Increased Risk of Benign Prostate Hyperplasia (BPH) in Patients with Gout: A Longitudinal Follow-Up Study Using a National Health Screening Cohort
- PMID: 38201364
- PMCID: PMC10871099
- DOI: 10.3390/diagnostics14010055
Increased Risk of Benign Prostate Hyperplasia (BPH) in Patients with Gout: A Longitudinal Follow-Up Study Using a National Health Screening Cohort
Abstract
A previous study reported a high risk of benign prostatic hyperplasia (BPH) in patients with gout. This study intended to evaluate the risk of BPH in gout patients. A total of 514,866 Korean National Health Insurance Service-Health Screening Cohorts were retrieved from 2002 to 2019. Among these individuals, 14,961 gout patients and 58,764 control participants were matched based on demographic factors. The incidence of BPH during the follow-up periods was collected for both the gout and control groups. The risk of BPH was analyzed using stratified Cox proportional hazard models, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Secondary analyses were conducted based on demographic factors and comorbidities. The incidence of BPH was 23.40% in gout patients and 20.70% in control participants. In the adjusted model, the HR of BPH was 1.13-fold higher in gout patients than in the control group (95% CI = 1.09-1.18). Compared with the ≥60-year-old group, the <60-year-old group demonstrated a higher HR for BPH in gout patients (1.19 [1.13-1.24] vs. 1.07 [1.01-1.13]). The risk of BPH in gout patients was consistent according to various comorbidities. Patients with gout demonstrated a greater risk of BPH than participants without gout. The young adult population had a higher risk of BPH related to gout.
Keywords: benign prostate hyperplasia; cohort studies; epidemiology; gout; risk factors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Association of alpha-1-adrenergic antagonist use with the risk of gout development in benign prostatic hyperplasia patients: a population-based cohort study.Fam Pract. 2022 May 28;39(3):426-431. doi: 10.1093/fampra/cmab163. Fam Pract. 2022. PMID: 34964888
-
Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study.Prostate Cancer Prostatic Dis. 2018 Jun;21(2):277-286. doi: 10.1038/s41391-018-0047-8. Epub 2018 Jun 1. Prostate Cancer Prostatic Dis. 2018. PMID: 29858589
-
Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.Prostate. 2018 Feb;78(2):113-120. doi: 10.1002/pros.23451. Epub 2017 Nov 9. Prostate. 2018. PMID: 29119583
-
Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.Medicine (Baltimore). 2016 May;95(18):e3493. doi: 10.1097/MD.0000000000003493. Medicine (Baltimore). 2016. PMID: 27149447 Free PMC article.
-
The natural history of benign prostatic hyperplasia.BJU Int. 2006 Apr;97 Suppl 2:3-6; discussion 21-2. doi: 10.1111/j.1464-410X.2006.06097.x. BJU Int. 2006. PMID: 16507045 Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources